Acquisitions and Divestitures (Details) (USD $)	6 Months Ended	1 Months Ended
	Jun. 30, 2012	Mar. 31, 2012 Avila Therapeutics, Inc.	Mar. 07, 2012 Avila Therapeutics, Inc.	Jun. 30, 2012 Avila Therapeutics, Inc. Maximum	Mar. 07, 2012 Avila Therapeutics, Inc. Maximum
Acquisitions
Payments for acquisition of business, net of cash acquired	$ 352,246,000	$ 352,200,000
Fair value of consideration transferred
Cash			363,405,000
Contingent consideration			169,337,000
Total fair value of consideration transferred			532,742,000
Potential milestone payment				595,000,000	595,000,000
Period within which amount recognized for asset and liabilities at acquisition will be finalized		1 year
Purchase price allocated to assets acquired and liabilities assumed at acquisition date based upon respective preliminary fair values
Working capital			11,987,000
Property, plant and equipment			2,559,000
Platform technology intangible asset			330,800,000
In-process research and development product rights			198,400,000
Net deferred tax liability			(164,993,000)
Total identifiable net assets			378,753,000
Goodwill			153,989,000
Net assets acquired			532,742,000
Amortization period of platform technology		Seven years
Current deferred income tax asset			14,700,000
Non-current deferred tax liability			$ 179,700,000